TVTXTravere Therapeutics, Inc.

Nasdaq travere.com


$ 6.30 $ -0.30 (-4.55 %)    

Friday, 10-May-2024 15:59:19 EDT
QQQ $ 441.71 $ 1.04 (0.24 %)
DIA $ 395.04 $ 1.18 (0.3 %)
SPY $ 520.76 $ 0.67 (0.13 %)
TLT $ 90.14 $ -0.51 (-0.56 %)
GLD $ 218.73 $ 1.76 (0.81 %)
$ 6.3
$ 6.72
$ 6.30 x 100
$ 0.00 x 0
$ 6.26 - $ 6.72
$ 5.12 - $ 19.54
974,836
na
485.96M
$ 0.93
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-06-2024 03-31-2024 10-Q
2 02-20-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-03-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 02-23-2023 12-31-2022 10-K
7 10-27-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-05-2022 03-31-2022 10-Q
10 02-24-2022 12-31-2021 10-K
11 10-29-2021 09-30-2021 10-Q
12 07-29-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 03-01-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 07-31-2020 06-30-2020 10-Q
17 05-11-2020 03-31-2020 10-Q
18 02-24-2020 12-31-2019 10-K
19 10-30-2019 09-30-2019 10-Q
20 08-06-2019 06-30-2019 10-Q
21 05-07-2019 03-31-2019 10-Q
22 02-26-2019 12-31-2018 10-K
23 11-01-2018 09-30-2018 10-Q
24 08-03-2018 06-30-2018 10-Q
25 05-01-2018 03-31-2018 10-Q
26 02-27-2018 12-31-2017 10-K
27 11-07-2017 09-30-2017 10-Q
28 08-09-2017 06-30-2017 10-Q
29 05-05-2017 03-31-2017 10-Q
30 03-01-2017 12-31-2016 10-K
31 11-04-2016 09-30-2016 10-Q
32 08-05-2016 06-30-2016 10-Q
33 05-05-2016 03-31-2016 10-Q
34 02-26-2016 12-31-2015 10-K
35 11-06-2015 09-30-2015 10-Q
36 08-10-2015 06-30-2015 10-Q
37 05-11-2015 03-31-2015 10-Q
38 03-11-2015 12-31-2014 10-K
39 11-13-2014 09-30-2014 10-Q
40 08-14-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-travere-therapeutics-maintains-19-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Travere Therapeutics (NASDAQ:TVTX) with a Buy and maintains $19 price tar...

 canaccord-genuity-maintains-buy-on-travere-therapeutics-raises-price-target-to-18

Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target fr...

 travere-therapeutics-q1-2024-adj-eps-151-misses-099-estimate-sales-41374m-miss-42847m-estimate

Travere Therapeutics (NASDAQ:TVTX) reported quarterly losses of $(1.51) per share which missed the analyst consensus estimate o...

 hc-wainwright--co-maintains-buy-on-travere-therapeutics-raises-price-target-to-19

HC Wainwright & Co. analyst Ed Arce maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target ...

 csl-vifor-and-travere-therapeutics-granted-european-commission-conditional-marketing-authorization-for-filspari-sparsentan-for-the-treatment-of-iga-nephropathy

First non-immunosuppressive therapy for the treatment of IgA Nephropathy (IgAN) approved in Europe Conditional marketing autho...

 reported-earlier-travere-therapeutics-and-ccl-vifor-get-european-commission-approval-of-sparsentan-for-the-treatment-of-iga-nephropathy

https://ec.europa.eu/transparency/documents-register/detail?ref=C(2024)2719&lang=en 

 wedbush-reiterates-outperform-on-travere-therapeutics-maintains-13-price-target

Wedbush analyst Laura Chico reiterates Travere Therapeutics (NASDAQ:TVTX) with a Outperform and maintains $13 price target.

 guggenheim-downgrades-travere-therapeutics-to-neutral

Guggenheim analyst Vamil Divan downgrades Travere Therapeutics (NASDAQ:TVTX) from Buy to Neutral.

 hc-wainwright--co-maintains-buy-on-travere-therapeutics-maintains-17-price-target

HC Wainwright & Co. analyst Ed Arce maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and maintains $17 price target.

 wedbush-reiterates-outperform-on-travere-therapeutics-maintains-13-price-target

Wedbush analyst Laura Chico reiterates Travere Therapeutics (NASDAQ:TVTX) with a Outperform and maintains $13 price target.

 travere-therapeutics-q4-adj-eps-094-beats-126-estimate-sales-4506m-beat-4151m-estimate

Travere Therapeutics (NASDAQ:TVTX) reported quarterly losses of $(0.94) per share which beat the analyst consensus estimate of ...

 earnings-scheduled-for-february-15-2024

Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on rev...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION